A blind spot in Ebola virus control: the sudden outbreak of Bundibugyo virus (BDBV). Bundibugyo virus (BDBV) has a relatively low incidence compared with Zaire or Sudan Ebola viruses, resulting in its marginalization in vaccine and precision antibody therapeutic development for Filovirus control. However, the recent rapid cluster-driven pandemic swiftly incapacitated local containment networks, and the early clinical presentation resembled common febrile illnesses, rendering early diagnosis impossible given the local medical infrastructure. The lack of data on mutation accumulation rates and transmission kinetics created a critical technical bottleneck, leading to failure of early isolation and a surge in mortality.

Field-deployable next-generation genomics: activation of an Oxford Nanopore Technologies (ONT)-based surveillance system. To overcome the physical time barrier of transporting specimens to central laboratories, the international consortium established an "in situ sequencing" pipeline using the field-deployable MinION platform. Viral RNA collected on site was converted to whole-genome sequence data within a few hours via nanopore sequencing immediately after reverse transcription (RT‑PCR). As molecular epidemiology data accumulated in real time, the genetic origins and lineage mutations of the outbreak strain could be mapped, and super‑spreading routes were traced using systems biology, enabling precise targeting of movement-restriction zones.

Structure-based antiviral cocktail screening and accelerated adaptive clinical trial. The identified BDBV glycoprotein variant sequences were instantly fed into an AI-driven structural prediction engine, which simulated changes in binding affinity to existing Ebola therapeutics (e.g., bebtelovimab, remdesivir derivatives). This enabled rapid selection of candidate compounds with anticipated cross‑reactivity, and an adaptive clinical trial design—modifying the protocol on the fly based on interim data without a fixed control arm—was launched in collaboration with local clinicians. The rapid validation protocol demonstrated partial clinical efficacy by significantly reversing viral load in terminal patients.

Establishing post‑pandemic standards and the rationale for modular platform therapeutics. This urgent outbreak R&D dataset is critically important because it unequivocally validates the effectiveness of a plug‑and‑play rapid response protocol required for unknown infectious threats (Disease X). It sets a precedent for an integrated genomics‑clinical platform that compresses the lead time from virus isolation through genome sequencing, structural simulation, and clinical entry to within weeks. Moreover, by demonstrating that swapping only the guide sequence or local database enables immediate deployment against any RNA virus, the value of a programmable response engine is proven, positioning it as a core reference for future global health security and next‑generation broad‑spectrum antiviral pipelines.